Necrotizing skin lesions and NABs development in a multiple sclerosis patient treated with IFNβ 1b

Multiple Sclerosis

Volumn 9, Issue 4, 2003, Pages 420-423

  Casoni, Federica ^a   Merelli, Elisa ^a   Bedin, Roberta ^a   Martella, Alessandro ^b   Cesinaro, Anna ^c   Bertolotto, Antonio ^d  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Clinica Dermatologica   (Italy)

^c Div di Anat E Istologia Patologica   (Italy)

^d SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

IFN 1b; Multiple sclerosis; NABs; Skin ulcers

Indexed keywords

ANTIBIOTIC AGENT; AVONEXT; BETA1A INTERFERON; CORTICOSTEROID DERIVATIVE; INTERFERON BETA SERINE; METHYLPREDNISOLONE; NEUTRALIZING ANTIBODY; PARACETAMOL;

ABDOMEN; ADULT; ARM; ARTICLE; BLOOD VESSEL; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INJECTION PAIN; INJECTION SITE; LEG ULCER; LYMPHOID TISSUE; MULTIPLE SCLEROSIS; RELAPSE; REMISSION; SIDE EFFECT; SKIN BIOPSY; SKIN DEFECT; SKIN INFILTRATE; SKIN NECROSIS; SKIN ULCER; SUBCUTANEOUS FAT; THIGH; THROMBOSIS; VASCULAR DISEASE;

ADJUVANTS, IMMUNOLOGIC; ADULT; FEMALE; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; NECROSIS; SKIN ULCER; VASCULITIS;

EID: 0042624739     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458503ms933sr     Document Type: Article

References (10)

1. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple sclerosis) study group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
2. Walther EU, Hohlfeld R. Multiple sclerosis side effects of interferon beta therapy and their management. Neurology 1999; 53: 1622-27.
3. Bertolotto A, Malucchi S, Mulano E, Castello A, Copobianco M, Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: Neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000; 48: 95-100.
4. Knobler RL, Kelley CL Interferon beta 1b induced ulcerative skin lesions in MS (abstract). J Neuroimmunol 1994; 54: 173.
5. Sheremata WA, Taylor JR, Elgart OW. Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. N Engl J Med 1995; 332: 1584.
6. Elgart OW, Shermata W, Ahn YS. Cutaneous reactions to recombinant human interferon beta-1b: The clinical and histologic spectrum. J Am Acad Dermatol 1997: 37: 553-57.
7. Radziwill AJ, Courvoisier S. Severe necritizing cutaneous lesions complicating treatment with interferon b. J Neurol Neurosurg Psychiatry 1999; 67: 115.
8. Cohen BA, Greenberger PA, Saini S. Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b. Allergy-Asthma Proc 1998; 19: 85-88.
9. Feldmann R, Low-Weiser H, Dushet P, Oschnait F. Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis. Dermatology 1997; 195: 52-53.
10. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-I b: Experience during the first three years. Neurology 1996; 47: 889-94.